BCR and neoplasm: Currently, downstream BCR signaling molecules (PKD2 or BTK), tumor cell-derived IL-18 cytokine, and Breg-cell-mediated IL-35 are utilized to target pro-tumorigenic suppressor B cells in PDAC.